Slide 1: Cover letter to BSE and NSE
July 12, 2021 Corporate Relationship Department Manager – Listing M/s. BSE Ltd M/s. National Stock Exchange of India Ltd Dalal Sreet, Fort “Exchange Plaza”, Bandra – Kurla Complex Mumbai 400 001 Bandra (E) Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir, Please find enclosed herewi
Slide 2: Natco Pharma Limited Investor Presentation Q4 2020-21
NATCO PHARMA LIMITED INVESTOR PRESENTATION Q4 2020-21 1
Slide 3: Disclaimer/Important Disclosure
DISCLAIMER/IMPORTANT DISCLOSURE THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background i
Slide 4: Business Overview
BUSINESS OVERVIEW Vertically integrated pharmaceutical company with presence across geographies - India, US and ROW Strong brand position in domestic pharma segments - Well established player in oncology with brands catering to diseases including breast, bone, lung and ovarian cancer - Growing prese
Slide 5: Performance at a Glance
PERFORMANCE AT A GLANCE Financial Performance(1) (2) ₹ million Ownership Structure(3) 4,409 2021 7,098 21,557 4,608 2020 6,900 Public, Promoter, 20,224 51.13% 48.87% 6,444 2019 9,250 22,247 6,962 2018 9,688 22,424 4,860 2017 6,973 20,789 1,571 2016 2,823 10,897 PAT EBIDTA Revenue 5 yr CAGR 22.9% 20.
Slide 6: Key Business Segments - Pharma
KEY BUSINESS SEGMENTS - PHARMA FORMULATIONS Domestic International Exports API (Domestic & Exports) Subsidiaries • Three key business segments: ◼ Focused on niche opportunities in ◼ Strategically important division ◼ Operations in Brazil, Oncology, Specialty Pharma, the US ◼ 39 active DMFs in the US
Slide 7: US Market - Focus on Complex Generics
US MARKET- FOCUS ON COMPLEX GENERICS KEY PRODUCTS IN THE PORTFOLIO STRATEGY FOR US MARKETS Therapeutic Segment / Primary Key Brand Molecule Indication ◼ Predominantly focused on high-barrier-to-entry products that are Copaxone Glatiramer Acetate CNS/Multiple Sclerosis typically characterized by one
Slide 8: Strong Growth in Domestic Business
STRONG GROWTH IN DOMESTIC BUSINESS DOMESTIC PRODUCT LAUNCHES IN FY 2021 DOMESTIC FORMULATION SALES(1) ₹ mn ◼ Launched 10 products during the year ◼ Leading player in branded oncology medicines in India ◼ Market leading positions across the Hep-C class of drugs in India, in spite of market size reduc
Slide 9: Strong Market Position in Domestic Oncology Segment
STRONG MARKET POSITION IN DOMESTIC ONCOLOGY SEGMENT OVERVIEW OF ONCOLOGY DIVISION ONCOLOGY REVENUE ₹ mn ◼ 18 years of strong presence in oncology segment. One of the leaders in the sale of branded oncology medicines in India ◼ Portfolio of well recognized brands – 7 brands with INR 100mn+ sales in t
Slide 10: Expanding ROW Presence
EXPANDING ROW PRESENCE CANADA ◼ Strong portfolio with 25+ products including Oncology, cardiovascular and CNS therapies ◼ 22 approvals in place ◼ Launched Nat-Lanthanum as the sole generic in the market SUBSIDIARIES PERFORMANCE ₹ mn BRAZIL 4,011 ▪ Launched the first generic of Oseltamivir in Brazil
Slide 11: API Facilities
API FACILITIES STRENGTHS ◼ Strategically important business – develops APIs primarily for third party sales and also for captive ▪ Well established process safety engineering lab consumption ▪ Complex multi-step synthesis & scale-up ◼ Portfolio of 39 active US DMFs with niche products under developm
Slide 12: Research & Development Capabilities
RESEARCH & DEVELOPMENT CAPABILITIES R&D capabilities demonstrated by its complex and niche product filings in formulations and API segments ◼ Two research facilities with capabilities across synthetic chemistry, nano pharmaceuticals, new drug discovery and FINISHED DOSAGE cell biology FORMULATIONS (
Slide 13: Formulation Facilities
FORMULATION FACILITIES INTERNATIONAL MARKETS KOTHUR VISAKHAPATNAM ◼ Oral and solid dosages including ◼ Solid oral tablet and capsule cytotoxic Orals, cytotoxic manufacturing injectables and pre-filled syringes ◼ Site approval received from USFDA. First ◼ USFDA, GMP, (DCA), German, Health product app
Slide 14: Crop Health Sciences
CROP HEALTH SCIENCES TECHNICAL UNIT ◼ Completed state-of-the-art greenfield manufacturing facilities for agro technical and formulation products, with a total Capex spend of approx. INR 152 crores ◼ Acquired manufacturing assets for production of pheromone-based formulations, with technology transfe
Slide 15: Key Management
KEY MANAGEMENT V.C Nannapaneni ◼ Holds a Masters degree in Pharmaceutical Administration from the Long Island University, USA Chairman and Managing Director ◼ Over 4 decades of experience in the pharmaceutical industry Rajeev Nannapaneni ◼ Holds a Bachelors degree in Quantitative Economics and Histo
Slide 16: Consolidated Financials
CONSOLIDATED FINANCIALS Consolidated Profit & Loss Statement (₹ mn) Consolidated Balance Sheet (₹ mn) Year ended 31 March 2021 31 March 2020 S.No. Particulars 31 March 2021 31 March 2020 I Assets Income (1) Non-current assets 1 Revenue from operations 20,521 19,150 (a) Property, plant and equipment
Slide 17: Quarterly Financial Summary
QUARTERLY FINANCIAL SUMMARY SEGMENTAL BREAKDOWN (₹ mn) CONSOLIDATED FINANCIAL RESULTS (₹ mn) Revenue Division Q4FY21 Q4FY20 FY21 FY20 FY19 Q4FY21 Q4FY20 FY21 FY20 FY19 A) API Revenue(1):- 708 964 5,120 3,552 3,019 Total Revenues 3,597 4,772 21,557 20,225 22,247 B) Formulation:- EBITDA 1,046 1,507 7,
Slide 18: A View of Natco's Corporate Office
Contact Investor Relations Team at ir@natcopharma.co.in 040-2354 7532; Extn 220 17 A VIEW OF NATCO’S CORPORATE OFFICE